Boehringer Ingelheim (BI), based in Germany, has announced a collaboration with U.S. drug discovery firm Ten63 Therapeutics, aimed at identifying multiple novel molecules across various indications with significant unmet medical needs. Financial details of the partnership have not been disclosed.
This collaboration will leverage BI’s extensive pre-clinical and clinical expertise alongside Ten63’s proprietary algorithms, which integrate pocket discovery with a generative chemistry engine. This innovative approach allows for the sampling of over 100 trillion synthetically feasible drug-like molecules against BI’s specified targets, potentially accelerating the development of new therapeutic options.- Flcube.com
